Abstract
IntroductionPatients undergoing acute percutaneous coronary intervention receive dual antiplatelet therapy for secondary prevention. Recurrent myocardial infarction or bleedings are possibly due to under- or overdosing of antiplatelet therapy in relation to body size. MethodsWe correlated residual platelet aggregation with body mass index, body surface area, lean body mass and blood volume in 220 patients on prasugrel (n = 121) or ticagrelor (n = 99). ResultsPlatelet aggregation outside the recommended window was recorded in 85 patients, but not correlated with any of the body indices. ConclusionBody size does not affect platelet response to prasugrel or ticagrelor at the guideline-recommended fixed dosages.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
